# A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

> **NCT04557098** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 194 (actual)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** Teclistamab

## Key facts

- **NCT ID:** NCT04557098
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-17
- **Primary completion:** 2021-11-09
- **Final completion:** 2027-05-28
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04557098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04557098, "A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04557098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*